Bayer HealthCare offers comprehensive support services for eligible patients who are prescribed their Bayer oncology drugs through several patient support programs, including its Oncology $0 Co-Pay Program, the REACH (Resources for Expert Assistance and Care Helpline) program, the Xofigo Access Services program, and the Aliqopa Resource Connections program.
Boehringer Ingelheim’s Gilotrif Patient Services includes a range of programs and services offered through the company’s Solutions Plus program. This program provides support, education, and reimbursement services to patients who are prescribed Gilotrif (afatinib), as well as to their providers.
Through its Access Support program, Bristol-Myers Squibb (BMS) offers a variety of oncology support options for patients receiving outpatient treatment in the United States and Puerto Rico.
Celgene Corporation offers patient support services for patients receiving Celgene medications through the Celgene Patient Support program. This program offers eligible patients a range of support services to access Celgene’s oncology drugs, regardless of their insurance status.
Clovis Oncology’s Rubraca Connections is a comprehensive patient support services program designed to help patients who are prescribed Rubraca (rucaparib) tablets. This includes coordinating Rubraca delivery and pick-up, finding financial support programs, and connecting patients with a specialty pharmacy team.
Coherus BioSciences’ Coherus COMPLETE offers comprehensive reimbursement and patient support services for patients receiving treatment with Udenyca (pegfilgrastim-cbqv) who are unable to afford the medication, along with provider service programs to help access Udenyca and secure patient reimbursements.
Daiichi-Sankyo offers comprehensive reimbursement and patient support services for patients who are prescribed Injectafer (ferric carboxymaltose injection) but are unable to afford it.
Eisai Reimbursement Resources is a program designed to offer drug-specific assistance related to the coding, coverage, and reimbursement of select Eisai drugs, as well as a variety of patient assistance services for patients who are prescribed Eisai’s drugs and who are having difficulty paying for the cost of their care.
EMD Serono and Pfizer provide the CoverOne program, a patient assistance program that offers reimbursement services, copay assistance, and billing and coding resources for patients who are prescribed Bavencio (avelumab), a fully human anti–PD-L1 monoclonal antibody.